Introduction and Background The Apotex filgrastim/pegfilgrastim biosimilar litigation was the first biosimilar litigation where the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
District Court
-
-
The battle over the proper forum for patent infringement litigation regarding Dupixent® (Dupilumab) appears to have been resolved. Last...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Genentech filed suit against Amgen this past February when a dispute arose between the parties during the first step of the “patent...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Editors’ Note: Although the BPCIA was enacted seven years ago, to date, only four biosimilar products have been approved by the FDA, and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported, Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. filed a Declaratory Judgment...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. (collectively “Plaintiffs”) filed a Complaint in the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Genentech’s lawsuit against Amgen has come to a quick (although perhaps temporary) end, with the Court dismissing Genentech’s complaint...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On February 15, 2017, Genentech filed litigation accusing Amgen of violating the Biologics Price Competition and Innovation Act...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]